You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 25, 2024

Investigational Drug Information for Ulixertinib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Ulixertinib?

Ulixertinib is an investigational drug.

There have been 10 clinical trials for Ulixertinib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 12th 2015.

The most common disease conditions in clinical trials are Glioma, Neoplasms, and Lymphoma. The leading clinical trial sponsors are BioMed Valley Discoveries, Inc, National Cancer Institute (NCI), and Dana-Farber Cancer Institute.

There are eighteen US patents protecting this investigational drug and two hundred and nine international patents.

Recent Clinical Trials for Ulixertinib
TitleSponsorPhase
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in AdultsBioMed Valley Discoveries, IncPhase 1
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in AdultsM.D. Anderson Cancer CenterPhase 1
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced GI MalignanciesBioMed Valley Discoveries, IncPhase 2

See all Ulixertinib clinical trials

Clinical Trial Summary for Ulixertinib

Top disease conditions for Ulixertinib
Top clinical trial sponsors for Ulixertinib

See all Ulixertinib clinical trials

US Patents for Ulixertinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ulixertinib ⤷  Sign Up Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH) ⤷  Sign Up
Ulixertinib ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Ulixertinib ⤷  Sign Up Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.